Cognitive Behavioral Therapy First-Line Treatment For Generalized Anxiety Disorder In Adults: JAMA
- byDoctor News Daily Team
- 03 July, 2025
- 0 Comments
- 0 Mins
 
                            
                                    Cognitive behavioural therapy first-line treatment for generalised anxiety disorder in adults suggests a new study published in the JAMA.
Generalized anxiety disorder (GAD) is one of the most common mental disorders in adults. Psychotherapies are among the most recommended treatments for GAD, but which should be considered as first-line treatment needs to be clarified.
The study was conducted to use a network meta-analysis to examine the short- and long-term associations of different psychotherapies with outcomes of effectiveness and acceptability in adults with GAD.
MEDLINE, Embase, PsycINFO, and the Cochrane Register of Controlled Trials were searched from database inception to January 1, 2023, to identify randomized clinical trials (RCTs) of psychotherapies for adults with GAD.
RCTs comparing any type of psychotherapy against another or with a control condition for the treatment of adults (≥18 years, both sexes) with a primary diagnosis of GAD were eligible for inclusion.
This study followed Cochrane standards for extracting data and assessing data quality and used the PRISMA guideline for reporting. Risk of bias of individual studies was assessed using the second version of the Cochrane risk of bias tool, and the Confidence in Network Meta-Analysis was used to rate the certainty of evidence for meta-analytical results.
Eight psychotherapies were compared against one another and with 2 control conditions. Primary outcomes were severity of GAD symptoms and acceptability of the psychotherapies. Random-effects model pairwise and network meta-analyses were conducted. For effectiveness, standardized mean differences (SMDs) were pooled, and for acceptability, relative risks with 95% CIs were calculated.
Results Data from 66 RCTs were included. Effect size estimates on data from 5597 participants (mean [SD], 70.9% [11.9%] women; mean [SD] age, 42.2 [12.5] years) suggested that third-wave cognitive behavior therapies (CBTs) (SMD, −0.78 [95% CI, −1.19 to −0.37]; certainty, moderate), CBT (SMD, −0.68 [95% CI, −1.05 to −0.32]; certainty, moderate), and relaxation therapy (SMD, −0.54 [95% CI, −1.04 to −0.05]; certainty, low) were associated with reduced GAD symptoms vs treatment as usual. Relative risks for all-cause discontinuation (indication of acceptability) signaled no differences compared with treatment as usual for all psychotherapies (eg, relative risk, 1.07 [95% CI, 0.73-1.57] for CBT vs treatment as usual). When excluding studies at high risk of bias, relaxation therapy lost its superiority over treatment as usual (SMD, −0.40; 95% CI, −1.15 to 0.34). When considering anxiety severity at 3 to 12 months after completion of the intervention, only CBT remained significantly associated with greater effectiveness than treatment as usual (SMD, −0.58; 95% CI, −0.93 to −0.23).
Given the evidence in this systematic review and network meta-analysis for its associations with both acute and long-term effectiveness, CBT may represent the first-line therapy of GAD. Third-wave CBTs and relaxation therapy were associated with short-term effectiveness and may also be offered.
Reference:
Papola D, Miguel C, Mazzaglia M, et al. Psychotherapies for Generalized Anxiety Disorder in Adults: A Systematic Review and Network Meta-Analysis of Randomized Clinical Trials. JAMA Psychiatry. Published online October 18, 2023. doi:10.1001/jamapsychiatry.2023.3971
Keywords:
Cognitive, behavioral, therapy, first-line, treatment, generalized, anxiety, disorder, adults, JAMA, JAMA Psychiatry, Papola D, Miguel C, Mazzaglia M
                                
    Disclaimer: This website is designed for healthcare professionals and serves solely for informational purposes.
    The content provided should not be interpreted as medical advice, diagnosis, treatment recommendations, prescriptions, or endorsements of specific medical practices. It is not a replacement for professional medical consultation or the expertise of a licensed healthcare provider.
    Given the ever-evolving nature of medical science, we strive to keep our information accurate and up to date. However, we do not guarantee the completeness or accuracy of the content.
    If you come across any inconsistencies, please reach out to us at 
    admin@doctornewsdaily.com.
    We do not support or endorse medical opinions, treatments, or recommendations that contradict the advice of qualified healthcare professionals.
    By using this website, you agree to our 
    Terms of Use, 
    Privacy Policy, and 
    Advertisement Policy.
    For further details, please review our 
    Full Disclaimer.
Tags:
Recent News
Merck Keytruda wins European Commission nod for lo...
- 30 October, 2025
UP NEET 2025 round 3 allotment results postponed
- 30 October, 2025
Achin Gupta to succeed Umang Vohra as Cipla MD, GC...
- 30 October, 2025
Mumbai shocker: KEM Hospital doctor stabbed by col...
- 30 October, 2025
Daily Newsletter
Get all the top stories from Blogs to keep track.
 
                     
                    
0 Comments
Post a comment
No comments yet. Be the first to comment!